INDIANAPOLIS, Aug. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 9, 2019 to discuss data presented for its RET-Inhibitor, LOXO-292, at the 20th meeting of the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer in Barcelona, Spain. Remarks will focus on registrational results from the LIBRETTO-001 trial, a Phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers. The webcast will begin at 7:00 p.m. Central European Time, or 1:00 p.m. Eastern Time.
Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/events.cfm. A replay will also be available on the website following the conference call.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels. F-LLY
Mark Taylor; email@example.com; (317) 276-5795 (Media)
Kevin Hern; firstname.lastname@example.org; (317) 277-1838 (Investors)
SOURCE Eli Lilly and Company
These press releases may also interest you